Table 1.
ORR and CRR in the primary and long-term analyses of L-MIND.
| Tafasitamab plus lenalidomide N = 80 b |
||
|---|---|---|
| Primary analysis Data cut-off: 30 November 201833 |
Follow-up analysis Data cut-off: 30 November 201942 |
|
| Best objective response, n (%) | ||
| CR | 34 (43) | 32 (40) |
| PR | 14 (18) | 14 (18) |
| ORR – CR + PR; n (%) (95% CI) a | 48 (60) (48–71) | 46 (58) (45.9–68.5) |
| Median DoR – IRC; months (95% CI) | 21.7 (21.7–NR) | 34.6 (26.1–34.6) |
| Median PFS – IRC; months (95% CI) | 12.1 (5.7–NR) | 12.1 (6.3–NR) |
| Median OS, months (95% CI) | NR (18.3–NR) | 31.6 (18.3–NR) |
a
Using the two-sided 95% Clopper–Pearson exact method based on a binomial distribution.
b
One patient received tafasitamab only and was excluded from 81 enrolled patients.
CI, confidence interval; CR, complete response; CRR, complete response rate; DoR, duration of response; IRC, independent review committee; NR, not reached; ORR, objective response rate; OS, overall survival; PFS, progression-free survival; PR, partial response.